News & Updates
Filter by Specialty:
DOACs, LMWH prevent VTE, but increase bleeding, in major noncardiac surgery
Use of direct oral anticoagulants (DOACs) and low molecular weight heparin (LMWH) appears to reduce venous thromboembolism (VTE) in major noncardiac surgery compared with no active treatment, a study has shown. However, it may also increase major bleeding to a similar extent.
DOACs, LMWH prevent VTE, but increase bleeding, in major noncardiac surgery
30 Mar 2022
SGLT2i better than DDP4i at preventing heart failure hospitalization, death in T2DM
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce hospitalization for heart failure (hHF) and all-cause death in type 2 diabetes mellitus (T2DM) patients without a history of cardiovascular disease, reports a new study.
SGLT2i better than DDP4i at preventing heart failure hospitalization, death in T2DM
29 Mar 2022
Do outpatient ophthalmologic procedures increase risk for acute MI?
Ophthalmologic procedures performed in an outpatient setting do not seem to heighten the risk for acute myocardial infarction (AMI), a study has shown.
Do outpatient ophthalmologic procedures increase risk for acute MI?
29 Mar 2022
BP-lowering drugs reduce death in older hypertensive COVID-19 patients
Antecedent use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) among older COVID-19 patients with hypertension results in fewer all-cause deaths, whether in-hospital or shortly after discharge, compared with no antecedent use of renin-angiotensin system inhibitors (RASIs), a study has shown.
BP-lowering drugs reduce death in older hypertensive COVID-19 patients
29 Mar 2022
Empagliflozin lowers mortality, cardiorenal events even in COPD presence
Among patients with type 2 diabetes mellitus and cardiovascular disease, those with concomitant chronic obstructive pulmonary disease (COPD) are at higher risk of mortality and adverse cardiorenal outcomes, including heart failure, according to post hoc analyses of the EMPA-REG OUTCOME trial. However, these outcomes can be prevented with empagliflozin treatment, regardless of the presence of COPD.
